论文部分内容阅读
目的探讨沙利度胺联合奈达铂治疗非小细胞肺癌(NSCLC)的临床疗效。方法选取2013年1月至2014年10月间收治的108例NSCLC患者作为研究对象,按照随机数字表法,将患者随机分为观察组和对照组,每组各54例。观察组患者采用奈达铂+沙利度胺治疗,对照组患者给予奈达铂治疗。比较两组患者的近期疗效、血清血管内皮生长因子(VEGF)、碱性成纤维生长因子(b FGF)、肿瘤坏死因子α(TNF-α)水平及不良反应。结果观察组患者近期治疗有效率为40.7%,与对照组(31.5%)比较,差异无统计学意义(P>0.05)。治疗后,观察组患者血清VEGF、b FGF、TNF-α水平均低于对照组,差异均有统计学意义(P<0.05)。观察组患者Ⅰ~Ⅱ度胃肠道不良反应发生率低于对照组,差异有统计学意义(P<0.05),而中性粒细胞减少、血红蛋白减少、血小板减少、肝功能损害等不良反应发生率差异均无统计学意义(均P>0.05)。结论沙利度胺联合奈达铂治疗NSCLC疗效确切,能够显著降低胃肠道不良反应发生率及血清VEGF、b FGF、TNF-α水平,临床上值得推广。
Objective To investigate the clinical efficacy of thalidomide combined with nedaplatin in the treatment of non-small cell lung cancer (NSCLC). Methods A total of 108 patients with NSCLC who were admitted between January 2013 and October 2014 were enrolled in this study. According to the random number table, patients were randomly divided into observation group and control group, 54 cases in each group. Patients in the observation group were treated with nedaplatin + thalidomide, and patients in the control group were treated with nedaplatin. The curative effect, serum VEGF, bFGF, TNF-α and adverse reactions were compared between the two groups. Results The effective rate of treatment in the observation group was 40.7%, which was not significantly different from that in the control group (31.5%) (P> 0.05). After treatment, the serum levels of VEGF, b FGF and TNF-α in the observation group were lower than those in the control group, with statistical significance (P <0.05). The incidence of gastrointestinal adverse reactions of Ⅰ ~ Ⅱ degree in observation group was lower than that of control group, the difference was statistically significant (P <0.05), while adverse reactions such as neutropenia, hemoglobin decrease, thrombocytopenia and liver dysfunction occurred There was no significant difference in rates (all P> 0.05). Conclusion Thalidomide combined with nedaplatin in the treatment of NSCLC is effective and can significantly reduce the incidence of gastrointestinal adverse reactions and serum levels of VEGF, b FGF and TNF-α, which are worthy of promotion in clinic.